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Abstract
FOXO transcription factors are key tumor suppressors in mammalian cells. Until now, suppression of FOXOs in cancer cells
was thought to be mainly due to activation of multiple onco-kinases by a phosphorylation-ubiquitylation-mediated
cascade. Therefore, it was speculated that inhibition of FOXO proteins would naturally occur through a multiple step post-
translational process. However, whether cancer cells may downregulate FOXO protein via an alternative regulatory
mechanism is unclear. In the current study, we report that expression of miR-96 was markedly upregulated in breast cancer
cells and breast cancer tissues compared with normal breast epithelial cells (NBEC) and normal breast tissues. Ectopic
expression of miR-96 induced the proliferation and anchorage-independent growth of breast cancer cells, while inhibition
of miR-96 reduced this effect. Furthermore, upregulation of miR-96 in breast cancer cells resulted in modulation of their
entry into the G1/S transitional phase, which was caused by downregulation of cyclin-dependent kinase (CDK) inhibitors,
p27
Kip1 and p21
Cip1, and upregulation of the cell-cycle regulator cyclin D1. Moreover, we demonstrated that miR-96
downregulated FOXO3a expression by directly targeting the FOXO3a 39-untranslated region. Taken together, our results
suggest that miR-96 may play an important role in promoting proliferation of human breast cancer cells and present a novel
mechanism of miRNA-mediated direct suppression of FOXO3a expression in cancer cells.
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Introduction
The FOXO subfamily of Forkhead transcription factors,
including FoxO1 (FKHR), FoxO3a (FKHRL1), FoxO4 (AFX)
and FoxO6 contains evolutionarily conserved transcriptional
activators that are characterized by a highly conserved forkhead
domain with a DNA-binding motif [1]. FOXO proteins play a
pivotal role in biological processes, such as apoptosis, cell cycle
control, differentiation, stress response, DNA damage repair and
glucose metabolism [2]. Activation of each member of the FOXO
subfamily in cells can upregulate cell-cycle inhibitors p21
Cip1 and
p27
Kip1 and downregulate the cell cycle regulator cyclin D1/2
(cell-cycle related genes), consequently leading to G1/S arrest of
cells [3–5]. It has been also reported that upregulation of FOXO
proteins can induce apoptosis through regulation of multiple pro-
apoptotic proteins, including Bim, Puma, Fas ligand and TRAIL
[6–9]. Meanwhile, FOXO proteins have been associated with
DNA damage repair via upregulation of GADD45a or interaction
with ATM to promote DNA repair via downstream mediators
[10–12]. Therefore, FOXO transcription factors are considered
key tumor suppressors. Indeed, downregulation of FOXO1 in
chicken embryo fibroblasts or inhibition of transcriptional activity
of FOXO3a protein in human breast cancer cells can promote cell
transformation and tumor progression [13–14]. Broad somatic
deletion of all FOXOs in mice were shown to promote a
progressive cancer-prone condition characterized by thymic
lymphomas and hemangiomas, and stable introduction of a
dominant-negative FOXO moiety into Em-myc transgenic hema-
topoietic stem cells could accelerate lymphoma development in
recipient mice [15–16]. These observations demonstrate that the
mammalian FOXOs are bona fide tumor suppressors.
The inhibition of cell proliferation and survival by FOXO
transcription factors is often abrogated due to high level activation
of multiple onco-kinases in cancer cells, such as Akt, SGK1
(serum-and glucocorticoid-inducible kinase 1) and IkB kinase
(IKK)-b [17,18,14]. Phosphorylation of FOXO transcriptional
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from the nucleus to cytoplasm through interaction with 14-3-3
chaperone proteins [19]. Although activation of the above-
mentioned onco-kinases can contribute to persistent phosphory-
lation and degradation of FOXO proteins, we wondered why
cancer cells would downregulate FOXO proteins via multiple
steps (such as phosphrylation, nuclear/cytoplasmic translocation,
and ubiquitin-mediated degradation) rather than halt synthesis at
the translational step as it is energy-consuming for the cell to
continually re-synthesize and re-degrade these proteins. Thus,
we hypothesized that there may be an alternative regulatory
mechanism of FOXO protein expression in cancer.
MicroRNAs (miRNAs), a class of small non-coding RNAs,
regulate gene expression by inhibition of translation or facilitation
of mRNA degradation that result in repression of target genes by
binding to the 39-UTR of a target mRNA molecule [20–21].
Numerous studies have reported that miRNAs are involved in the
development and progression of various types of human cancers
and proposed as potential novel targets for anti-cancer therapies
[22–24].
In the current study, the expression of miR-96 in breast cancer
cells was compared to that in normal tissue, and the effect of its
overexpression on the proliferation of tumor cells was investigated.
We determined that miR-96 likely promotes breast cancer
proliferation by directly targeting the 39untranslated region (39-
UTR) of the FOXO3a mRNA, consequently reducing the
expression of cyclin-dependent kinase (CDK) inhibitors, p27
Kip1
and p21
Cip1, and upregulating the cell-cycle regulator cyclin D1.
Our results suggest that miR-96 may play an important role in the
development and progression of breast cancer.
Materials and Methods
Ethics Statement
Normal breast samples. Normal breast samples was
collected from the mammoplasty material of a 30-year-old
woman and approved by the Sun Yat-sen University and First
Affiliated Hospital Institutional Board. Samples was collected and
analyzed with written informed consent.
Breast cancer tissue specimens. This study was conducted
on a total of 23 breast cancer samples which were histopath-
ologically and clinically diagnosed at the Sun Yat-sen University
Cancer Center from 2009 to 2010. Clinical and clinicopath-
ological classification and staging were determined according to
the American Joint Committee on Cancer (AJCC) criteria [25].
The stage and grade of primary breast tumors were as follows: 3
cases at stage I of disease, 12 at stage II, 7 at stage III, and 1 at
stage IV. Of these breast cancers samples, 14 were ERa-positive,
16 were PR-positive, and 18 were HER2-positive. For the use of
clinical materials for research purposes, prior patients’ consents
and approval was obtained from the Sun Yat-sen University
and Cancer Center Institutional Board. All samples were collected
and analyzed with prior written informed consent from the
patients.
Cell Culture
Primary NBEC, form mammoplasty material, were cultured in
the Keratinocyte serum-free medium (Invitrogen, Carlsbad, CA)
supplemented with epithelial growth factor, bovine pituitary
extract and antibiotics (120 mg/ml streptomycin and 120 mg/ml
penicillin). Breast cancer cell lines, including MCF-7, ZR-75-30,
BT549, Bcap37, MDA-MB435, SKBR3, MDA-MB453 and
T47D, were maintained in DMEM medium (Invitrogen, Carls-
bad, CA) supplemented with 10% fetal bovine serum (HyClone,
Logan, UT) and 1% penicillin/streptomycin (Invitrogen, Carls-
bad, CA, USA).
Plasmid and transfection
The full-length sequence of FOXO3a-39UTR is 4977 base pairs
(bp) long and contains two conserved miR-96 binding sites (REs),
including RE#1 from 76 bp to 80 bp, and RE#2 from 916 bp to
922 bp; one reported miR-155 binding site from 1021 bp to
1027 bp [26]; two reported miR-182 binding sites (REs), including
RE#1 from 73 bp to 79 bp, and RE#2 from 915 bp to 921 bp
[27]. The region of human FOXO3a 39UTR, from 47 to 939,
generated by PCR amplification from NBEC, were cloned into the
Sac I/Xma I sites of the pGL3-basic luciferase reporter plasmid
(Promega, Madison, WI) and pGFP-C3 (Clontech, Mountain
View, CA). The primers selected are as the following: FOXO3a-
39UTR-wt-up: 59- AAGACCTACAGAGAAAACCCTTTGCC-
AAATCTGCTCTC AGC-39; FOXO3a-39UTR-wt-dn: 59-CTA-
AACCCTTTAGTGACATTTGGCAATGAGTGG CCCGG-39;
FOXO3a-39UTR-mu-up: 59-AAGACCTACAGAGAAAACCC-
TTTGCCACC TCTGCTCTCAGC-39; FOXO3a-39UTR-mu-
dn: 59-CTAAACCCTTTAGTGACATGGGGC AATGAGTG-
GCCCGGG-39; p3x IRS-MLP-luc plasmid was constructed as
previously described [28]. The miR-96 mimics, negative control,
and anti-miR-96 inhibitor were purchased from RiboBio (RiboBio
Co.Ltd, Guangzhou, Guangdong). Transfection of microRNA or
microRNA inhibitor was performed using the Lipofectamine 2000
reagent (Invitrogen) according to the manufacturer’s instruction.
Western blotting
The western blot analysis was performed according to standard
methods as previously described [29], using anti-FOXO3a, anti-
p21, anti-p27, anti-cyclinD1, anti-Ki-67 antibodies (Cell Signaling,
Danvers, MA), and anti-Rb, anti- phosphorylated Rb antibodies
(Abcam, Cambridge, MA). The membranes were stripped and re-
blotted with an anti-a-tubulin monoclonal antibody (Sigma, Saint
Louis, MO) as a loading control.
RNA Extraction and Real-Time Quantitative PCR
Total miRNA from cultured cells and fresh surgical breast
cancer tissues was extracted using the mirVana miRNA Isolation
Kit (Ambion, Austin, TX, USA) according to the manufacturer’s
instructions. cDNA was synthesized from 5 ng of total RNA using
the Taqman miRNA reverse transcription kit (Applied Biosystems,
Foster City, CA), and the expression levels of miR-96 were
quantified using miRNA-specific TaqMan MiRNA Assay Kit
(Applied Biosystems). Real-time PCR was performed using
the Applied Biosystems 7500 Sequence Detection system. The
primers selected are as the following: p21
Cip1, forward, 59-CG-
ATGCCAACCTCCTCAACGA -39, and reverse, 59-TCGCAG-
ACCT CCAGCATCCA-39; p27
Kip1, forward, 59-TGCAACC-
GA CGATTCTTCTACTCAA-39, and reverse, 59-CAAGCAG-
TGATGTATCTGATAAACAAGG A-39; cyclin D1, forward, 59-
AAC TACCTGGACCGCTTCCT -39, and reverse, 59-CCA-
CTT GAGCTTGTTCACCA-39). Expression data were normal-
ized to the geometric mean of housekeeping gene GAPDH
to control the variability in expression levels (forward primer,
59-GACTCATGACCACAGTCCATGC-39; reverse primer, 39-
AGAGGCAGGGATGATG TTCTG -59) and calculated as
2
-[(Ct of p21, p27, or cyclin D1) – (Ct of GAPDH)], where Ct represents the
threshold cycle for each transcript. The expression of miRNA was
defined based on the threshold cycle (Ct), and relative expression
levels were calculated as 2
-[(Ct of miR-96) – (Ct of U6)] after
normalization with reference to expression of U6 small nuclear
RNA.
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bromide (MTT) assay
Cells, seeded on 96-well plates, were stained at indicated time
point with 100 ml sterile MTT dye (0.5 mg/ml, Sigma) for 4 h at
37uC, followed by removal of the culture medium and addition of
150 ml of dimethyl sulphoxide (DMSO) (Sigma, St. Louis, MO,
USA). The absorbance was measured at 570 nm, with 655 nm as
the reference wavelength. All experiments were performed in
triplicates.
Anchorage-independent growth ability assay
Five hundred cells were trypsinized and suspended in 2 ml
complete medium plus 0.3% agar (Sigma, St Louis, MO). The
agar–cell mixture was plated on top of a bottom layer with 1%
complete medium agar mixture. After 10 days, viable colonies that
contained more than 50 cells or were larger than 0.1 mm were
counted. Colony size was measured with an ocular micrometer
and colonies greater than 0.1 mm in diameter were counted. The
experiment was performed for three independently times for each
cell line.
Colony formation assays
Cells were plated on 6-well (0.5610
3 cells per plate) and
cultured for 10 days. The colonies were stained with 1.0% crystal
violet for 30s after fixation with 10% formaldehyde for 5 min.
Bromodeoxyuridine labeling and immunofluorescence
Cells grown on coverslips (Fisher, Pittsburgh, PA) were
incubated with bromodeoxyuridine (BrdUrd) for 1 h and stained
with anti-BrdUrd antibody (Upstate, Temecula, CA) according to
the manufacturer’s instruction. Gray level images were acquired
under a laser scanning microscope (Axioskop 2 plus, Carl Zeiss
Co. Ltd., Jena, Germany).
Luciferase assays
Cells (3.5610
4) were seeded in triplicates in 24-well plates and
allowed to settle for 24 h. One hundred nanogram of p3x IRS-
MLP -luciferase plasmid, or pGL3-FOXO3a-39UTR(wt/mu), or
the control-luciferase plasmid, plus 1 ng of pRL-TK renilla
plasmid (Promega, Madison, WI), were transfected into breast
cancers using the Lipofectamine 2000 reagent (Invitrogen Co.,
Carlsbad, CA) according to the manufacturer’s recommendation.
Luciferase and renilla signals were measured 48 h after transfec-
tion using the Dual Luciferase Reporter Assay Kit (Promega,
Madison, WI) according to a protocol provided by the
manufacturer. Three independent experiments were performed
and the data are presented as the mean 6 SD.
Flow cytometry analysis
All cells in a culture dish were harvested by trypsinization,
washed in ice-cold PBS, and fixed in 80% ice-cold ethanol in PBS.
Before staining, the cells were spun down in a cooled centrifuge
and resuspended in the cold. Bovine pancreatic RNAase (Sigma-
Aldrich) was added at a final concentration of 2 mg/ml, and cells
were incubated at 37uC for 30 min, followed by incubation in
20 mg/ml of propidium iodide (Sigma-Aldrich) for 20 min at room
temperature. 50,000 cells were analyzed on a flow cytometer
(FACSCalibur; BD Biosciences).
Statistical analysis
The Student’s t -test was used to evaluate the significant
difference of two groups of data in all the pertinent experiments. A
P value ,0.05 (using a two-tailed paired t test) was thought to be
significantly different for two groups of data.
Results
miR-96 is overexpressed in breast cancer cell lines and
breast cancer tissues
Real-time PCR analyses revealed that miR-96 was significantly
overexpressed in all nine examined breast cancer cell lines,
including BT549, ZR-75-30, Bcap37, MDA-MB231, MDA-
MB435, MCF-7, SKBR3, MDA-MB453 and T47D, as com-
pared with that in normal breast epithelial cells (NBEC)
(Figure 1A). Furthermore, comparative analysis revealed that
miR-96 was differentially overexpressed in 15 examined samples
paired with adjacent non-cancerous tissues from the same patient
(Figure 1B), indicating that miR-96 is upregulated in breast
cancer.
Upregulation of miR-96 enhances proliferation and
tumorigenicity of breast cancer cells
To investigate the biological role of miR-96 expression in the
development and progression of breast cancer, we next transfected
breast cancer cells MCF-7 and ZR-75-30 with hsa-miR-96 mimic
oligonucleotides and examined its effect on cellular proliferation.
By using MTT and colony formation assays, we observed that
overexpression of miR-96 dramatically increased the growth rate
of both breast cancer cells as compared with that of negative
control (NC) transfected cells (Figure 1C and 1D). Furthermore,
the expression of Ki-67, a well-known proliferative marker, was
dramatically increased in miR-96 overexpressing-MCF-7 and -
ZR-75-30 breast cancer cells compared with that in NC
transfected cells (Figure 1E), suggesting that upregulation of
miR-96 specifically promotes the proliferation of breast cancer
cells. Moreover, ectopically expressing miR-96 in MCF-7 and ZR-
75-30 breast cancer cells significantly enhanced their anchorage-
independent growth ability, as indicated by the increase in colony
numbers and sizes (Figure 1F), suggesting that upregulation of
miR-96 could augment the tumorigenicity of breast cancer cells
in vitro.
Overexpression of miR-96 regulates G1/S phase
transition of breast cancer cells
To further explore the ability of miR-96 to promote cell
proliferation, we analyzed miR-96 overexpressing MCF-7 and
ZR-75-30 cells by flow cytometry, which showed a significant
decrease in the percentage of cells in the G1/G0 peak and an
increase in the percentage of cells in the S peak (Figure 2A).
Furthermore, a higher percentage of miR-96 transfected MCF-7
cells (41.5%) and of miR-96 transfected ZR-75-30 cells (44.7%)
showed newly synthesized DNA by the BrdUrd incorporation
assay compared with MCF-7 control cells (26.2%) and ZR-75-30
control cells (30.5%) (Figure 2B). Collectively, our data suggest
that enhancement of breast cancer cell growth by miR-96 may be
mediated through regulation of cellular entry into the G1/S
transitional phase.
miR-96 downregulates cell-cycle inhibitors p21
Cip1 and
p27
Kip1 and upregulates cell cycle regulator cyclin D1
It is well known that CDK inhibitors p21
Cip1 and p27
Kip1 and
CDK regulator cyclin D1 are critical in the regulation of G1/S
transition [3–5]. Strikingly, the Western blotting and real-time
PCR analyses revealed that p21
Cip1 and p27
Kip1 were downreg-
ulated and cyclin D1 was upregulated at both protein and mRNA
Upregulation of miR-96 Promotes Proliferation
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15797Figure 1. Upregulation of miR-96 promoted proliferation of breast cancer cells. A, Real-time PCR analysis of miR-96 expression in normal
breast epithelial cells (NBECs) and breast cancer cell lines, including BT549, ZR-75-30, Bcap37, MDA-MB231, MDA-MB435, MCF-7, SKBR3, MDA-MB453
and T47D. B, The expression of miR-96 was examined in 15 paired breast tumor tissues (tumor) and their adjacent normal tissues (normal). The
average miR-96 expression was normalized by U6 expression. Each bar represents the mean of three independent experiments. C, Effects of miR-96
overexpression on the growth of breast cancer cells MCF-7 and ZR-75-30. MTT assays revealed that miR-96-transfected cells proliferated more rapidly
than the vector control cells. D, Representative micrographs (left) and quantification (right) of crystal violet stained cell colonies. E, Quantification of
Ki-67 positive cells in MCF-7 and ZR-75-30 cells transfected with miR-96 mimic and negative control (NC). F, Upregulation of miR-96 promoted breast
cancer cell tumorigenicity as determined by anchorage-independent growth assay. Representative micrographs (left) and quantification of colonies
that contained more than 50 cells (middle) or were larger than 0.1 mm (right) were scored. Each bar represents the mean of three independent
experiments. * P,0.05.
doi:10.1371/journal.pone.0015797.g001
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(Figure 2C and 2D). In parallel, the phosphorylation level of Rb, a
downstream target protein of CDK, was associated with the
change of expression levels of the abovementioned cell-cycle
regulators, further supporting the notion that miR-96 plays an
important role in the growth of breast cancer cells (Figure 2C).
Figure 2. miR-96 induced proliferation through increasing the proportion of S phase cells. A, Flow cytometric analysis of
indicated breast cancer cells transfected with miR-96 mimic or NC. B, Representative micrographs (left) and quantification of BrdU
incorporating-cells after transfection with miR-96 or NC. C, Western blotting analysis of expression of p21
Cip1,p 2 7
Kip1, cyclin D1, phosphorylated
Rb (p-Rb) and total Rb protein in indicated cells. a-tubulin was used as a loading control. D, Real-time PCR analysis of expression of p21
Cip1,
p27
Kip1, cyclin D1 in indicated cells. GAPDH was used as a loading control. Error bars represent mean 6 SD from three independent experiments.
* P,0.05.
doi:10.1371/journal.pone.0015797.g002
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cancer cells
The effect of inhibiting miR-96 on the proliferation of breast
cancer cells was further examined. As shown in Figure 3A,
suppression of miR-96 could increase the mRNA expression of
p21
Cip1 and p27
Kip1 while decrease the cyclin D1 transcriptional
level. Ectopically expressing the miR-96 inhibitor drastically
increased the percentage of cells in the G0/G1 peak but decreased
that in the S peak, indicating that inhibition of miR-96 induced
G1/S arrest of breast cancer cells (Figure 3B). Moreover, the
growth rates in MCF-7 and ZR-75-30 breast cancer cells after
transfection with the hsa-miR-96 inhibitor were slower than that
of NC transfected cells, as analyzed by an MTT assay (Figure 3C).
Inhibition of miR-96 in MCF-7 and ZR-75-30 cells also
significantly reduced the anchorage-independent growth of both
breast cancer cell lines, as shown by the decrease in the colony
numbers and colony sizes (Figure 3D).
miR-96 directly targets the transcriptional factor FOXO3a
in breast cancer cells
It has been demonstrated that the transcriptional factor
FOXO3a can upregulate the expression of p21
Cip1 and p27
Kip1
Figure 3. Inhibition of miR-96 suppressed the proliferation of breast cancer cells. A, Real-time PCR analysis of expression of p21
Cip1,
p27
Kip1 and cyclin D1 in indicated cells. GAPDH was used as a loading control. Error bars represent mean 6 SD from three independent experiments.
B, Flow cytometric analysis of indicated breast cancer cells transfected with miR-96 inhibitor or NC. C, MTT assays revealed that inhibition of miR-96
reduced cell growth. D, Representative micrographs (left) and quantification of colonies that contained more than 50 cells (middle) or were larger
than 0.1 mm (right) determined by anchorage-independent growth assays. Each bar represents the mean of three independent experiments.
* P,0.05.
doi:10.1371/journal.pone.0015797.g003
Upregulation of miR-96 Promotes Proliferation
PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e15797and downregulate cyclin D1 at the transcriptional level [3–5],
which prompted us to investigate whether the modulations of p27
Kip1, p21
Cip1 and cyclin D1 levels by miR-96 are caused by the
regulation of FOXO3a. Analysis using three publicly available
algorithms (TargetScan, Pictar, miRANDA) indicated that
FOXO3a is the theoretical target gene of miR-96 (Figure 4A).
As predicted, ectopic expression of miR-96 in MCF-7 and ZR-75-
30 cells decreased the expression of FOXO3a protein and the
FOXO3a transcriptional activity, respectively (Figure 4B and 4C),
indicating that upregulation of miR-96 results in the downregu-
lation and decreased transactivity of FOXO3a. Consistent with
this result, we found that FOXO3a was downregulated in the
breast cancer cells where mir-96 was upregulated (Figure S1 and
Figure 1A). Furthermore, we subcloned the FOXO3a 39-
untranslated region (39-UTR) fragment containing the two miR-
96 binding sites (REs) into the pEGFP-C3 and pGL3 dual
luciferase reporter vectors. As shown in Figure 4D, ectopic
expression of miR-96 in MCF-7 and ZR-75-30 breast cancer cells
dramatically inhibited the GFP protein expression, but not the
expression of GFP-c-tubulin that was used as a control for
transfection efficiency, suggesting that miR-96 specifically affected
the FOXO3a-39 UTR. Meanwhile, a consistent and dose-
dependent reduction of luciferase activity was observed upon
miR-96 transfection in both breast cancer cell lines (Figure 4E).
Moreover, point mutations in the tentative miR-96-binding seed
region in FOXO3a 39-UTR abrogated the suppressive effect of
FOXO3a mediated by miR-96 (Figure 4E). Taken together, our
results demonstrate that FOXO3a is a bona fide target of miR-96.
As expected, the luciferase levels of pGL3-FOXO3a-39UTR in
both breast cancer cell lines were restored after transfection with
the miR-96 inhibitor (Figure 5A). Inhibiting miR-96 also resulted
in the upregulation of FOXO3a proteins (Figure 5B). As shown by
the luciferase reporter assay, inhibition of miR-96 decreased
transactivities of FOXO3a in a dose-dependent manner in both
breast cancer cell lines (Figure 5C), indicating that inhibition of
miR-96 results in upregulation and increased transactivity of
FOXO3a.
FOXO3a plays an important role in miR-96-induced
proliferation of breast cancer cells
In the attempt to understand the role of FOXO3a repression in
miR-96-induced proliferation, the effects of FOXO3a (without 39-
UTR) and FOXO3a-39-UTR (with 39-UTR) were examined in the
miR-96-overexpressing cells. As predicted, ectopically expressing
FOXO3a significantly abrogated the miR-96 mediated-modula-
tions of cell-cycle regulators, p27
Kip1, p21
Cip1 and cyclin D1, but
overexpression of FOXO3a-39-UTR only partially attenuated the
regulation of the abovementioned cell-cycle regulators by miR-96
overexpression (Figure 6A). In particular, the luciferase activity of
FOXO3a reporter in miR-96-transfected cells could be rescued by
overexpressing FOXO3a, while it was slightly restored by
transfection with FOXO3a-39-UTR (Figure 6B). Moreover, the
MTT assay showed that co-transfection of miR-96 and FOXO3a
significantly slowed the growth rate of both breast cancer cell lines
(Figure 6C). However, the combination of FOXO3a-39-UTR and
miR-96 in the breast cancer cells had no obvious effect on the
growth rate over that of breast cancer cells transfected only with
miR-96 (Figure 6C). Taken together, our results suggest that
suppression of FOXO3a plays an important role in promotion of
cellular proliferation by miR-96.
Figure 4. miR-96 downregulated FOXO3a via directly targeting the FOXO3a 39UTR. A, Predicted miR-96 target sequences in 39-UTR of
FOXO3a (FOXO3a) and mutant containing two mutated nucleotides in 39-UTR of FOXO3a (FOXO3a-mu). B, Western blotting analysis of FOXO3a
expression in indicated cells. C, Relative FOXO3a reporter activities in the indicated cell lines. D, Western blotting analysis of GFP expression in
indicated cells. E, Luciferase assays on MCF-7 or ZR-75-30 breast cancer cells transfected with the pGL3 control reporter, pGL3-FOXO3a-39UTR
reporter, or pGL3-FOXO3a-39UTR-mu reporter and increasing amounts of miR-96 mimic oligonucleotides (20, 50 nM), as indicated. Error bars
represent mean 6 SD from three independent experiments. * P,0.05.
doi:10.1371/journal.pone.0015797.g004
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supported by observations in human primary tumors, the
expression levels of miR-96, p27
Kip1, cyclin D1, and FOXO3a
were examined in new freshly prepared two normal human breast
tissues and eight human breast tumor tissues. As shown in
Figure 6D and 6E, miR-96 expression and cyclin D1 mRNA
expression were markedly upregulated, but the expression levels of
p27
Kip1 mRNA and FOXO3a protein were downregulated in
breast tumors tissues as compared with those in normal human
breast tissues. The miR-96 expression positively correlated with
cyclin D1 (r=0.7392, P,0.01), whereas it negatively correlated
with p27
Kip1 (r=–0.7327, P,0.01). Furthermore, statistical
Figure 5. Inhibition of miR-96 activated the FOXO3a pathway. A, Luciferase activity assay of indicated cells transfected with the pGL3-
FOXO3a-39UTR reporter with increasing amounts (20, 50 nM) of miR-96 mimic- or miR-96 inhibitor-oligonucleotides. B, Western blotting analysis of
FOXO3a expression in indicated cells. C, Relative FOXO3a reporter activities in the indicated cell lines. Error bars represent mean 6 SD from three
independent experiments. * P,0.05.
doi:10.1371/journal.pone.0015797.g005
Figure 6. FOXO3a plays an important role in miR-96-induced proliferation. A, The expression of p21
Cip1, p27
Kip1 and cyclin D1 in indicated
cells using real-time PCR analysis. GAPDH was used as a loading control. B, Relative FOXO3a reporter activity in the indicated cell lines. C, The growth
rate of breast cancer cells transfected with miR-96 mimic, or mixed miR-96 and FOXO3a, or mixed miR-96 and FOXO3a-39-UTR. D, Real-time PCR
analysis of expression of miR-96, p27 and cyclin D1. E, Expression of FOXO3a, Ki67 (upper) and correlation (lower) analysis of miR-96, FOXO3a, Ki-67 in
two normal human breast tissues and eight freshly prepared human breast cancer tissues. * P,0.05.
doi:10.1371/journal.pone.0015797.g006
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correlated with FOXO3a (r=20.7577, P,0.001) but also
significantly correlated with the Ki-67 level (r=0.7151,
P,0.001) (Figure 6E), which further strengthened the notion that
miR-96 mediates proliferation of breast cancer through suppres-
sion of the transcriptional factor FOXO3a.
Discussion
The key finding of the current study is that miR-96 expression
was markedly upregulated in breast cancer cells and breast cancer
tissues as compared with that in normal breast epithelial cells and
normal breast tissues. We further found that ectopic expression of
miR-96 could enhance the proliferation and anchorage-indepen-
dent growth of breast cancer cells, while inhibition of miR-96
reduced these effects. Moreover, we demonstrated that upregula-
tion of miR-96 in breast cancer cells led to the downregulation of
cyclin-dependent kinase (CDK) inhibitors, p27
Kip1 and p21
Cip1,
and upregulation of the cell-cycle regulator cyclin D1 through
downregulation of FOXO3a via directly targeting the 39-UTR of
FOXO3a. These findings suggest that deregulation of miR-96
may play an important role in promoting carcinogenesis and
progression of breast cancer.
It has been reported that more than one million women are
diagnosed with breast cancer, and more than 400,000 patients die
due to the disease in the world each year [30]. To date, breast
cancer is the most common malignancy diagnosed among women
worldwide, and it is the second leading cause of cancer death.
Although both genetic and environmental factors are considered
to be major causes of breast cancer, the molecular mechanism of
its development and progression remain largely unknown [31–32].
As a member of the forkhead transcriptional factor family,
FOXO3a is a key tumor suppressor in breast cancer [33]. It has
been reported that upregulation of FOXO3a in breast cancer cells
exerts a general inhibitory effect on cell growth [14]. Zou and
colleagues demonstrated that functional interaction between
FOXO3a and ER plays an important role in inhibiting
estrogen-dependent breast cancer cell growth and tumorigenesis
in vivo [34]. Activation of FOXO3a, by paclitaxel, antibodies
against EGFR (cetuximab)/HER2 (trastuzumab), or mitogen-
activated protein/extracellular signal-regulated kinase kinase
(MEK) 1/2 inhibitor, results in apoptosis in breast cancer cells,
indicating that activation of FOXO3a inhibits proliferation and
development of breast cancer [35–37]. Consistent with these
reports, downregulation of FOXO3a could significantly augment
IKKb-mediated tumor growth in nude mice and lead to apoptosis
resistance in conjunction with elevated glycolysis that is the
important for tumor growth and survival, suggesting that
FOXO3a is a determinant of tumor progression and chemother-
apeutic response [14,38]. Collectively, all these studies indicate
that activation of FOXO3a may be a potential therapeutic
intervention strategy for breast cancer.
miRNAs, a class of small regulatory RNA molecules that
negatively regulate their mRNA targets in a sequence-specific
manner, have been demonstrated to play important roles in
multiple biological processes, such as cellular differentiation,
proliferation, oncogenesis, angiogenesis, invasion and metastasis,
and can function as either tumor suppressors or oncogenes
[22–24]. In the current study, we found that miR-96 was
significantly overexpressed in breast cancer cell lines as compared
with that in NBEC. Meanwhile, the expression of miR-96 was
shown to be upregulated in breast cancer tissues in comparison to
that in adjacent non-cancerous tissues from the same patient.
Furthermore, we demonstrated that ectopic expression of miR-96
drastically increased the growth rate of MCF-7 and ZR-75-30 cells
over that of control cells, while suppression of miR-96 inhibited
cell proliferation and the colony-forming ability of the cells on soft
agar, indicating that upregulation of miR-96 may correlate with
clinical breast cancer progression and function as an onco-
miRNA. In fact, the expression level of miR-96 is frequently
upregulated in various human tumor types, including colorectal
cancer, hepatocellular tumors (HCC) and chronic myeloid
leukemia cells [39–41].
Through bioinformatics analysis, the tumor suppressor
FOXO3a gene was indicated as a theoretical targeted gene of
miR-96. We were able to determine that FOXO3a is a bona fide
target of miR-96 by three different methods. Western blotting
analysis showed that overexpression of miR-96 resulted in the
decrease of FOXO3a protein. Real-time PCR analysis determined
that the downstream targets of FOXO3a, including cell-cycle
inhibitors p21
Cip1 and p27
Kip1 were significantly downregulated,
while the regulator cyclin D1 was upregulated in miR-96
transfected breast cancer cells. The luciferase activity assay and
point mutation analysis demonstrated that the downregulation of
FOXO3a was mediated by miR-96 through the FOXO3a-
39UTR. Furthermore, ectopically expressing FOXO3a (without
39UTR) significantly abrogated the miR-96-induced proliferation,
but transfection with FOXO3a-39-UTR (with 39UTR) only
partially attenuated the proliferative enhancement by miR-96
overexpression, suggesting that the effect of miR-96 on prolifer-
ation of breast cancer cells may be though downregulation of
FOXO3a via directly targeting the FOXO3a 39-UTR. The
biological function of miR-96 in protection against apoptosis and
cell survival, as related to FOXO3a function, is currently under
investigation in our laboratory.
Recently, several miRs were found to be involved in the
regulation of the FOXO family of transcription factors. It was
reported that miR-27a, miR-96, and miR-182 coordinately
regulate the expression of FOXO1 through directly targeting the
FOXO1 39-UTR [42]. miR-155 was shown to regulate cell
survival, growth and hemosensitivity by downregulating FOXO3a
in breast cancer [27]. Wang and colleagues reported that
upregulation of FOXO3a results in a decrease in miR-21 expres-
sion and suppressing its oncogenic activity, which further supports
the notion that FOXO3a functions as a tumor suppressor [43].
Interestingly, Yu and colleagues found that miR-96 was down-
regulated in pancreatic cancer and functions as a tumor
suppressor gene. However, we did not observe the obvious
change of KRAS expression in breast cancer cells transfected with
miR-96 (Data not shown), suggesting that a single miRNA may
have several distinct functions in different cell types, which likely
depends on the availability of specific targets or downstream
effectors, as suggested by Hyun et al. and Betel et al. [44–45].
Indeed, it has been reported that miR-26 is amplified in high-
grade glioma and facilitates gliomagenesis through downreregula-
tion of the tumor suppressor PTEN [46]. However, Ji and
colleagues found that miR-26 was downregulated and was
associated with hepatocellular carcinoma via activation of the
NF-kB pathway [47]. Meanwhile, overexpressing miR-30 could
inhibit apoptosis through repression of p53 expression in
cardiomyocytes [48], but upregulation of miR-30 in breast cancer
cells induced apoptosis by targeting Ubc9 [49].
In summary, the current study provides, for the first time, an
important link between miR-96-mediated proliferation of breast
cancer cells and downregulation of FOXO3a. Our findings
suggest an essential role of miR-96 in the regulation of breast
cancer cells proliferation. Understanding the precise role played by
miR-96 in breast cancer progression will not only increase our
Upregulation of miR-96 Promotes Proliferation
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allow development of a novel therapeutic strategy.
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MB435, MCF-7, SKBR3, MDA-MB453 and T47D. a-tubulin
was used as a loading control.
(TIF)
Author Contributions
Conceived and designed the experiments: XW LS. Performed the
experiments: HL TD HX. Analyzed the data: DT XZ XC CY. Wrote
the paper: JL LS.
References
1. Greer EL, Brunet A (2005) FOXO transcription factors at the interface between
longevity and tumor suppression. Oncogene 24: 7410–25.
2. Huang H, Tindall DJ (2007) Dynamic FoxO transcription factors. J Cell Sci 120:
2479–87.
3. Medema RH, Kops GJ, Bos JL, Burgering BM (2000) AFX-like Forkhead
transcription factors mediate cell-cycle regulation by Ras and PKB through
p27kip1. Nature 404: 782–787.
4. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, et al. (2002) Control
of cell cycle exit and entry by protein kinase B-regulated forkhead transcription
factors. Mol Cell Biol 22: 2025–2036.
5. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ,
et al. (2002) Cell cycle inhibition by FoxO forkhead transcription factors involves
downregulation of cyclin D. Mol Cell Biol 22: 7842–7852.
6. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, et al. (2006)
FOXO3a-dependent regulation of Puma in response to cytokine/growth factor
withdrawal. J Exp Med 203: 1657–63.
7. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ (2000)
Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the
forkhead transcription factor FKHR-L1. Curr Biol 10: 1201–1204.
8. Yang JY, Xia W, Hu MC (2006) Ionizing radiation activates expression of
FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol 29:
643–648.
9. Modur V, Nagarajan R, Evers BM, Milbrandt J (2002) FOXO proteins regulate
tumor necrosis factor-related apoptosis inducing ligand expression. Implications
for PTEN mutation in prostate cancer. J Biol Chem 277: 47928–47937.
10. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr., et al. (2002) DNA
repair pathway stimulated by the forkhead transcription factor FOXO3a
through the Gadd45 protein. Science 296: 530–534.
11. Sakoe Y, Sakoe K, Kirito K, Ozawa K, Komatsu N (2010) FOXO3A as a key
molecule for all-trans retinoic acid-induced granulocytic differentiation and
apoptosis in acute promyelocytic leukemia. Blood 115: 3787–95.
12. Tsai WB, Chung YM, Takahashi Y, Xu Z, Hu MC (2008) Functional
interaction between FOXO3a and ATM regulates DNA damage response. Nat
Cell Biol 10: 460–7.
13. Aoki M, Jiang H, Vogt PK (2004) Proteasomal degradation of the FoxO1
transcriptional regulator in cells transformed by the P3k and Akt oncoproteins.
Proc Natl Acad Sci U S A 101: 13613–7.
14. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, et al. (2004) IkappaB kinase
promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117:
225–237.
15. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, et al. (2007) FoxOs are lineage-
restricted redundant tumor suppressors and regulate endothelial cell homeosta-
sis. Cell 128: 309–23.
16. Bouchard C, Lee S, Paulus-Hock V, Loddenkemper C, Eilers M, et al. (2007)
FoxO transcription factors suppress Myc-driven lymphomagenesis via direct
activation of Arf. Genes Dev 21: 2775–87.
17. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell
survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell
96: 857–868.
18. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, et al. (2001) Protein kinase
SGK mediates survival signals by phosphorylating the forkhead transcription
factor FKHRL1 (FOXO3a). Mol. Cell. Biol 21: 952–965.
19. Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, et al. (2002) 14-3-3 transits to
the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol
156: 817–828.
20. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350–355.
21. Bartel DP (2004) MicroRNAs. Genomics, biogenesis, mechanism, and function.
Cell 116: 281–297.
22. Gregory RI, Shiekhattar R (2005) MicroRNA biogenesis and cancer. Cancer
Res 65: 3509–12.
23. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev
Cancer. pp 857–66.
24. Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in
cancer. Nat Rev Cancer 6: 259–269.
25. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, et al. (2002) Breast
cancer: in AJCC Cancer Staging Handbook. TNM Classification of Malignant
Tumors. 6th edition. New York: Springer Verlag. pp 255–81.
26. Kong W, He L, Coppola M, Guo J, Esposito NN, et al. (2010) MicroRNA-155
regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in
breast cancer. J Biol Chem 285: 17869–79.
27. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, et al. (2009) Aberrant
miR-182 expression promotes melanoma metastasis by repressing FOXO3 and
microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 106:
1814–9.
28. Tang ED, Nun ˜ez G, Barr FG, Guan KL (1999) Negative regulation of the
forkhead transcription factor FKHR by Akt. J Biol Chem 274: 16741–6.
29. Li J, Zhang N, Song LB, Liao WT, Jiang LL, et al. (2008) Astrocyte elevated
gene-1 is a novel prognostic marker for breast cancer progression and overall
patient survival. Clin Cancer Res 14: 3319–26.
30. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:
532–42.
31. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, et al. (1995) Histological
grading of breast carcinomas: a study of interobserver agreement. Hum Pathol
26: 873–9.
32. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic
Index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207–19.
33. Accili D, Arden KC (2004) FoxOs at the crossroads of cellular metabolism,
differentiation, and transformation. Cell 117: 421–426.
34. YiyuZou, Wen-BinTsai, Chien-JuiCheng, ChiunHsu, Young MinChung, et al.
(2008) Forkhead box transcription factor FOXO3a suppresses estrogen-
dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer
Research 10: R21–34.
35. Real PJ, Benito A, Cuevas J, Berciano MT, de Juan A, et al. (2005) Blockade of
epidermal growth factor receptors chemosensitizes breast cancer cells through
up-regulation of Bnip3L. Cancer Res 65: 8151–7.
36. Sunters A, Ferna ´ndez de Mattos S, Stahl M, Brosens JJ, et al. (2003) FoxO3a
transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast
cancer cell lines. J Biol Chem 278: 49795–805.
37. Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, et al. (2010) Activation of
FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-
regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res
70: 4709–18.
38. Khatri S, Yepiskoposyan H, Gallo CA, Tandon P, Plas DR (2010) FOXO3a
regulates glycolysis via transcriptional control of tumor suppressor TSC1. J Biol
Chem 285: 15960–5.
39. Bandre ´s E, Cubedo E, Agirre X, Malumbres R, Za ´rate R, et al. (2006)
Identification by Real-time PCR of 13 mature microRNAs differentially
expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5: 29; 1–10.
40. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, et al. (2010) miR-221
overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107:
264–9.
41. Agirre X, Jime ´nez-Velasco A, San Jose ´-Ene ´riz E, Garate L, Bandre ´s E, et al.
(2008) Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+
cells increases USF2-mediated cell growth. Mol Cancer Res 6: 1830–40.
42. Guttilla IK, White BA (2009) Coordinate regulation of FOXO1 by miR-27a,
miR-96, and miR-182 in breast cancer cells. J Biol Chem 284: 23204–16.
43. Wang K, Li PF (2010) Foxo3a regulates apoptosis by negatively targeting miR-
21. J Biol Chem 285: 16958–66.
44. Hyun S, Lee JH, Jin H, Nam J, Namkoong B, et al. (2009) Conserved
MicroRNA miR-8/miR-200 and its target USH/FOG2 control growth by
regulating PI3K. Cell 139: 1096–108.
45. Betel D, Koppal A, Agius P, Sander C, Leslie C (2010) Comprehensive modeling
of microRNA targets predicts functional non-conserved and non-canonical sites.
Genome Biol 11: R90.
46. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, et al. (2009) The
PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and
facilitates gliomagenesis in vivo. Genes Dev 23: 1327–37.
47. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression,
survival, and response to interferon in liver cancer. N Engl J Med 361: 1437–47.
48. Li J, Donath S, Li Y, Qin D, Prabhakar BS, et al. (2010) miR-30 regulates
mitochondrial fission through targeting p53 and the dynamin-related protein-1
pathway. PLoS Genet 6: e1000795.
49. Yu F, Deng H, Yao H, Liu Q, Su F, et al. (2010) Mir-30 reduction maintains
self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 29:
4194–204.
Upregulation of miR-96 Promotes Proliferation
PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e15797